<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069197</url>
  </required_header>
  <id_info>
    <org_study_id>maes 004</org_study_id>
    <nct_id>NCT02069197</nct_id>
  </id_info>
  <brief_title>Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea</brief_title>
  <acronym>KGDobesity</acronym>
  <official_title>Evaluation of Efficacy and Safety of Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mid-Atlantic Epilepsy and Sleep Center, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mid-Atlantic Epilepsy and Sleep Center, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of ketogenic diet (KD)&#xD;
      treatment of (i) obesity, (ii) type 2 diabetes mellitus and (iii) obstructive sleep apnea&#xD;
      (OSA) in patients with obesity and Type 2 DM and in patients with obesity and/or OSA. This&#xD;
      will be a randomized, open-label three arm controlled study comparing weight loss in obese&#xD;
      participants with type 2 diabetes and/or obstructive sleep apnea treated for 9 months with&#xD;
      3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day diet (Group A) with weight loss in&#xD;
      participants treated with orlistat 120 mg TID and lifestyle intervention consisting of&#xD;
      dietary advice, recommended caloric goal of 1600 kcal/day (Group B), and in participants&#xD;
      treated with only lifestyle intervention consisting of dietary advice, recommended caloric&#xD;
      goal of 1600 kcal/day (Group C).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study sample will be randomized into three treatment arms, KD (Group A, n=50), Orlistat&#xD;
      120 mg TID (Group B, n=50) and dietary and lifestyle counseling (Group C, n=50) in a 1:1:1&#xD;
      ratio. Each arm will include 100% participants with obesity and co-morbid type 2 DM and 50%&#xD;
      participants with co-morbid OSA. Randomization will be stratified for diabetic status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of body mass index from baseline in 9 months period</measure>
    <time_frame>9 months</time_frame>
    <description>The change of weight and the BMI(body mass index) will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose blood level in patients with diabetes mellitus in 9 months.</measure>
    <time_frame>9 months</time_frame>
    <description>HbA1C, fasting serum glucose insulin and leptin levels and fasting lipid levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of apnea/hypopnea index in patients with obstructive sleep apnea in patients with obesity</measure>
    <time_frame>9 months</time_frame>
    <description>For participants with OSA, secondary outcome will include polysomnogram-derived apnea/hypopnea index.&#xD;
Level of alertness will be evaluated with Epworth Sleepiness Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety of ketogenic diet as a treatment of obesity.</measure>
    <time_frame>9 months</time_frame>
    <description>Evaluate in serum levels of beta-hydroxybutyrate, glucose, electrolytes, renal and liver functions, uric acid, HbA1C, serum lipid profile, insulin and leptin levels, CRP.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Obesity</condition>
  <condition>Diabetes</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Ketogenic diet, lifestyle counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketogenic diet consisted of 3:1[fat]:[protein+carbohydrate] weight ratio with 1600kcal restriction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat, Lifestyle counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat 120 mg TID, standardized diet and lifestyle-modification counseling based on the LEARN (Life, Exercise, Attitudes, Relationships,and Nutrition) program with recommended caloric goal of 1600 kcal/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standartized diet, Lifestyle counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standardized diet and lifestyle-modification counseling based on the LEARN (Lifestyle, Exercise, Attitudes, Relationship, Nutrition) program with recommended caloric goal of 1600kcal/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ketogenic diet</intervention_name>
    <description>ketogenic diet will consist of 3:1[fat]:[protein+carbohydrate]weight ratio with 1600 kcal restriction. Diet will last 9 months.</description>
    <arm_group_label>Ketogenic diet, lifestyle counseling</arm_group_label>
    <other_name>high fat, low protein, low carbohydrate diet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <description>Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.</description>
    <arm_group_label>Orlistat, Lifestyle counseling</arm_group_label>
    <other_name>tetrahydrolipstatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized diet</intervention_name>
    <description>Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.</description>
    <arm_group_label>Standartized diet, Lifestyle counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-70&#xD;
&#xD;
          -  ability and willingness to signed informed consent form&#xD;
&#xD;
          -  BMI more than 30kg/m2, with type 2 DM and/or OSA&#xD;
&#xD;
          -  For diabetic participants, stable hypoglycemic medications for at least 2 months&#xD;
&#xD;
          -  For participants with OSA, previously documented polysomnogram with apnea/hypopnea&#xD;
             index (AHI)&gt;15/h.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI change of +/- 3.0 kg/m2 of baseline BMI within past 12 months.&#xD;
&#xD;
          -  History of bariatric surgery â‰¤ 3 years prior to enrollment.&#xD;
&#xD;
          -  Any systemic illness or unstable medical condition that might pose additional risk,&#xD;
             including: cardiac, unstable metabolic or endocrine disturbances, renal or liver&#xD;
             disease, past history of renal calculi, hyperuricemia, hypercalcemia, mitochondrial&#xD;
             disease, known disorder of fatty acid metabolism, porphyria, and active systemic&#xD;
             cancer.&#xD;
&#xD;
          -  History of uncontrolled hyperlipidemia&#xD;
&#xD;
          -  For participants with DM, change in the dose or type of hypoglycemic treatment within&#xD;
             2 months prior to enrollment.&#xD;
&#xD;
          -  Psychosis within six months of enrollment, evidenced by treatment with anti-psychotic&#xD;
             medications with recent medication initiation or dose increase.&#xD;
&#xD;
          -  Active drug or alcohol dependence or any other factors that, in the opinion of the&#xD;
             site investigators would interfere with adherence to study requirements;&#xD;
&#xD;
          -  History of hyperthyroidism&#xD;
&#xD;
          -  History of glaucoma&#xD;
&#xD;
          -  History of cerebrovascular disease or unstable heart disease within 6 months of&#xD;
             enrollment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of any investigational drugs within 3 months of enrollment.&#xD;
&#xD;
          -  Inability or unwillingness of subject to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Klein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid-Atlantic Epilepsy and Sleep center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivana Tyrlikova, MD</last_name>
    <phone>301-530-9744</phone>
    <email>tyrlikovai@epilepsydc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arcady Barber, MSCN</last_name>
    <phone>301-530-9744</phone>
    <email>barbera@epilepsydc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mid-Atlantic Epilepsy and Sleep Center, LLC</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Tyrlikova, MD</last_name>
      <phone>301-530-9744</phone>
      <email>tyrlikovai@epilepsydc.com</email>
    </contact>
    <contact_backup>
      <last_name>Arcady Barber, MSCN</last_name>
      <phone>301-530-9744</phone>
      <email>barbera@epilepsydc.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 19, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mid-Atlantic Epilepsy and Sleep Center, LLC</investigator_affiliation>
    <investigator_full_name>Pavel Klein</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ketogenic diet</keyword>
  <keyword>obesity</keyword>
  <keyword>diabetes</keyword>
  <keyword>obstructive sleep apnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

